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Subsequent to the demonstration by Ng and Vane (1, 2)  that angiotensin I  (AI)  1 
is rapidly converted to the active form, angiotensin II (AII), in the canine lung, evi- 
dence obtained by infusing AI into various regional circulations in the dog (3-6) has 
indicated  that some conversion also occurs at extrapulmonary sites.  In the rat,  con- 
flicting results have been reported.  Whereas Barrett and Sambhi (7)  concluded that 
AI, at  physiological concentrations,  is  converted  almost  quantitatively  to  AII  in 
a single passage through the rat lung,  converting enzyme activity has been demon- 
strated  in homogenates of many rat tissues  (8),  and Freer and Stewart  (9)  have re- 
cently reported that the pulmonary vasculature in this species does not appear to be in- 
volved in the conversion of AI. 
Circulating antibodies directed against AII have been much used in analyzing 
the pressor function of the renin-angiotensin system in rat renal-clip hyperten- 
sion  (10-13).  However,  the  interpretation  of such  studies  requires  an  under- 
standing of the relative extent to which the pressor activity of renin, in the in- 
tact animal,  is dependent  upon free-circulating AII generated in  the lungs, as 
distinct from AII released locally from AI at extrapulmonary sites, or intrinsic 
activity of the decapeptide (14-16). 
Accordingly, we have investigated the dose-response characteristics of AI ad- 
ministered intra-arterially  and intravenously, both before and after AII block- 
ade by specific antibody, to determine whether AI can elicit a  systemic pressor 
response before lung transit.  An attempt was also made to distinguish between 
a direct action of AI and one mediated by peripheral formation of AII. 
Materials and Methods 
Four groups of male Wistar rats (250-450 g) were anesthetized with Inactin (100 mg/kg, 
i.p.; Promonta,  Hamburg),  tracheotomized, vagotomized, and injected with atropine  sulfate 
(1.5 mg/kg, i.m.) and pentolinium tartrate (25 mg/kg, i.m.). Two polyethylene catheters  (PE 
10) were inserted through the right jugular vein into the superior vena cava. 
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Groups I and 2.--The right common carotid artery was catheterized (PE 50) and connected 
via a Statham pressure transducer to a Sanborn recorder for continuous monitoring of arterial 
pressure.  Dose-response curves were determined  for  intravenous  AII  (1-Asn-5-Val-angioten- 
sin II, Hypertensin, Ciba), and AI (5-Ile-angiotensin I, Schwarz Bio Research Inc., Orange- 
burg, N. Y.), by measuring peak pressor responses  to a series of 4-8 injections of each peptide, 
given alternately. Doses of AI were expressed  as ng of an equimolar amount of AII (i.e.,  ng of 
AI +  1.25). 
Group 1 (five animals);  effect of control plasma on intravenous AII and A I  responses:  Dose- 
response curves for intravenous AII and AI were repeated after intravenous administration of 
0.3 ml of pooled normal rabbit plasma. 
Group 2  (eight animals);  effect of anti-AH  plasma  on intravenous  All  and  AI  responses: 
Dose-response curves were repeated after intravenous administration of 0.3 ml of rabbit anti- 
AII plasma. Larger doses of both peptides were required to obtain a similar range of responses. 
Anti-AII plasma used in the experiments in Groups 2-4 was collected from three rabbits im- 
munized by repeated injections, over 10 mo, of AII (1 mg/rabbit) coupled to bovine serum al- 
bumin and emulsified  in Freund's adjuvant (13). By methods of immunologic evaluation pre- 
viously described (13), the plasma was found to have a very high anti-AII titer of 1/233,000 
and cross-reactivity of 4.4% with AI. 
Groups 3 and 4.--In these animals one femoral artery was catheterized (PE 50) for arterial 
pressure measurement. The right common carotid artery was also catheterized (polyethylene, 
ID 0.35 ram,  OD 1.05 mm) and the catheter tip advanced until contact with the base of the 
left ventricle was detected by pulsation transmitted through the catheter; it was then with- 
drawn 3 mm. At the end of each experiment the animal was sacrificed,  and  the catheter tip 
shown to lie freely within the ventricular cavity, with no damage to aortic valve cusps or ven- 
tricular muscle.  Injections via the left ventricular catheter are described  as "intra-arterial", 
since  it was assumed that they would pass,  well mixed with blood,  into the systemic arterial 
circulation. 
Group 3  (eight animals);  effect of anti-AII  plasma  on intravenous  and  intra-arterial  AI re- 
sponses:  Dose-response curves for both intravenous and  intra-arterial AI were determined 
before and after infusion of 0.3 ml of anti-II plasma. 
Group 4 (two animals);  effect of converting enzyme inhibitor  on AI responses:  These experi- 
ments were carried out as for Group 3, with the additional step that, after the second  pair of 
dose-response  curves had been completed, the rats were injected intravenously with 0.4 mg of 
SQ 20,881  (Squibb Institute for Medical Research), a synthetic nonapeptide that inhibits en- 
zymatic conversion of AI to AII, both in vivo and vitro, leaving responses  to AII unaltered (6). 
Dose-response curves for both intravenous and intra-arterial AI were immediately repeated. 
RESULTS 
In each rat studied,  the log dose/response  relationships  for AI and AII were 
linear  in  the  range  5-25  mm  Hg.  The potency  of AI relative  to  AII,  and  the 
potency of intra-arterial AI relative to that of intravenous AI, did not vary sig- 
nificantly  throughout  the  dose-response  ranges  tested.  Thus,  to  compare  po- 
tencies,  the  regression  equation  of each  dose-response  curve  was  solved  for  a 
pressure rise of 15 mm Hg (the midpoint of the range tested), and the mean dose 
required  to  elicit  this  response  was  determined  for  each  group.  These  doses, 
hereafter called reference doses, are shown in Table I. 
Groups  1  and  2.--Before  infusion  of  plasma,  in  all  experiments,  AII  was 
slightly more potent than AI, as evidenced by the higher doses of AI required to 
produce  an  equipressor effect (Table  I).  In  Group  1,  administration  of control 
rabbit plasma did not change this relationship, and had no effect on basal blood HELEN  F.  OATES  AND  GORDON  S.  STOKES  81 
pressure readings. Nor, in Group 2, did infusion of anti-AII plasma change basal 
blood pressure. However, it resulted in a 36-fold increase in the reference dose of 
All, while that of AI increased only 10-fold, to a  value less than  that of All. 
The dose-response curves obtained in a  typical Group 2 experiment are shown 
in Fig. 1,  first panel. It is clear that,  after administration of anti-AlI plasma, 
the pressor potency of AI greatly exceeded that of All, and  that the relative 
positions of the curves were reversed. A  similar reversal was observed in every 
other experiment in this group. The AII antibody was only 29 -4- 3  (SE) %  as 
TABLE I 
Mean Dose* (4- SE) of Angiotensin  (ng) Req~dred  to Elicit a 15 mm Hg Rise in Arterial Pressure, 
Before and After Infusion of Normal Plasma (in Group 1), or Anti-AlI Plasma 
(in Groups 2 and 3) 
Factor of 
Group  No. animals  Peptide  Route  Before plasma (B)  After plasma (A)  increase in 
dosage (A/B) 
1  Five  AII  i.v.  1.7  -4- 0.2  1.7  ±  0.2  1.0 
AI  i.v.  2.1  4- 0.2  2.1  q-  0.2  1.0 
2  Eight  AII  i.v.  2.0  4-  0.4  71.6  +  15.3  35.8 
AI  i.v.  3.4  ±  0.6  35.2  ±  7.7  10.3 
3  Eight  AI  i.v.  3.0  +  0.4  30.4  q-  3.8  10.1 
AI  i.a.  4.3  ~  0.5  19.6  4-  2.5  4.6 
* Calculated by solution of log-dose response regressions. 
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FIG.  1.  Dose-response  curves  before  and  after  anti-AII  plasma.  Typical  dose-response 
curves before immunization (continuous lines), and after infusing anti-AII plasma (interrupted 
lines), in a  bioassay rat from Group 2  (first panel), and another from Group 3  (second panel), 
determined by injection of intravenous AII (i.v. AID, intravenous AI (i.v. AI), or intra-arterial 
AI (i.a. M). Doses of AI are expressed as ng of an equimolar amount of AII (i.e., ng of AI  + 
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effective in blocking AI given intravenously as it was in blocking AII injected by 
the same route. 
Groups 3 and 4.--In all  Group 3  experiments, before administration of AII 
antibody, AI was less potent when given by intra-arterial injection than when 
given intravenously (i.a./i.v. reference doses for equipressor effects =  143 % 4- 
8 SE; P  <  0.001).  There was however, no detectable difference between the 
intra-arterial route and the intravenous route with respect to the time taken for 
AI to produce the peak pressure rise (21 sec -4- 1 SE from the start of injection 
of intra-arterial AI, and 22  4-  1 for intravenous AI, over the response range 
10-25 ram Hg; P  >  0.3). 
After the injection of anti-AII plasma, the reference dose of intravenous AI 
increased 10-fold,  as found in Group 2, while the reference dose of intra-arterial 
AI increased only five-fold, to a value 64 % of that of the intravenous AI (P < 
0.05).  There was, again, no significant difference between the two routes of in- 
jection with respect to the time taken from the start of injection to the peak of 
the pressor response (intra-arterial AI, 20 sec 4- 2 SE; intravenous 21 sec 4- 1; 
P  >  0.7).  In every experiment, however,  the  relative positions of the  intra- 
venous and intra-arterial AI curves were reversed after AII antibody, as shown 
in Fig. 1, second panel. The AII antibody was only 45 4- 4 (SE) % as effective in 
blocking intra-arterial AI as in blocking intravenous AI. 
In Group 4 experiments, reversal of the relative positions of the intravenous 
and intra-arterial  AI curves occurred in the  presence of AII antibody,  as  in 
Group 3. Following injection of converting enzyme inhibitor (SQ 20,  881),  blood 
pressure fell by 6 mm Hg, but returned to the original basal level in less than  2 
rain. Immediate repetition of the dose-response curves revealed that all AI re- 
sponses had been abolished. No responses were elicited by doses of AI as high as 
100 ng, whether given by the intravenous or the intra-arterial route. 
DISCUSSION 
The finding that anti-AII plasma neutralized AII more effectively than it did 
AI, when the peptides were given intravenously (Group 2), is consistent with 
our previous finding in  rats  actively immunized  against AII (13).  There  are 
several possible explanations for this result: 
(a) The 5-Ile-angiotensin  II, liberated by conversion from the decapeptide injected, 
may not have as great an affinity for the antibody as the 1-Asn-5-Val-angiotensin  II 
used for comparison.  However, some anti-II antibodies do not discriminate between 
5-Val-AII and 5-Ile-AII (17). (b) AI may have intrinsic  activity that remains unim- 
paired by specific AII antibody.  (c) Injection of intravenous  AI may result  in the 
liberation of AII (whether in  the pulmonary bed,  or at extrapulmonary sites  even 
closer to tissue  receptors) nearer its site of action than the intravenous bolus of  AII 
with which it was compared. This would minimize  exposure  of the newly generated 
AII to the circulating AII antibody, and so increase its relative potency. HELEN  F.  OATES  AND  GORDON  S.  STOKES  83 
The Group 3 and 4 experiments were designed to overcome the multiple in- 
terpretations to which those of Group 2 were subject, and to make possible a dis- 
tinction between the alternative explanations. Firstly, since 5-Ile-angiotensin I 
was used throughout, differing affinities of the liberated AII for the antibody 
cannot explain the changed relationship between intravenous and intra-arterial 
responses. Secondly, though recent work has suggested that angiotensin I  may 
have a  significant central vasomotor action in  the vertebral artery territory 
(16), and a marked direct stimulatory effect on the adrenal medulla (15),  the 
fact that  injection of converting enzyme inhibitor  (Group 4)  abolished  both 
intravenous and intra-arterial AI responses over the entire dose range studied, 
makes it extremely unlikely that any direct intrinsic action of AI was contribut- 
ing to the rapid systemic pressor responses measured in Groups 2-4. 
The finding that, in the presence of AII antibody, intra-arterial AI became more 
potent than intravenous AI, can, then, only be explained in terms of conversion of the 
decapeptide  to AII.  There was  no delay in  the pressor  peak resulting  from intra- 
arterial AI injection such as would be expected if its activity resulted from recirculation 
and  conversion  in  the lung.  Moreover, if AI  was  completely  dependent upon pul- 
monary conversion for its activation, being inert before lung transit, it would be im- 
possible for the potency of intra-arterial AI to exceed that of intravenous AI, as found 
in all Group 3 experiments.  Indeed, since intra-arterially injected AI would have to 
recirculate,  being exposed to inactivation by angiotensinases, tissue uptake, and cross- 
reaction with the circulating  AII antibody along its path, before reaching a position 
equivalent to the intravenous injection site, lower potency would be expected. 
The results therefore make it clear that AI cannot be completely dependent 
upon pulmonary conversion for its activity, and that intra-arterial AI must, in 
fact, be converted to AII at extrapulmonary sites to cause rapid systemic pressor 
responses at least of sufficient magnitude to account for the differences between 
the intra-arterial  and  intravenous curves obtained after AII antibody in  the 
Group 3 experiments. 
Significance  of  Extrapulmonary  Angiolensin  Conversion.--Having  invoked 
extrapulmonary conversion of AI to AII  to  explain  the  findings in Groups 3 
and 4, it then becomes apparent why the potency of intra-arterially injected AI 
actually exceeded that of intravenous AI in the presence of specific AII antibody. 
AII generated from AI in the arteriolar vascular tree, nearer the tissue receptor 
sites, was clearly less exposed to neutralization by the circulating AII antibody 
than was the AII released in the pulmonary circulation from AI injected intra- 
venously. This, and the finding that specific antisera to AII neutralize intra- 
venously injected AII to a far greater extent than they do intra-arterially in- 
jected AII (Oates and Stokes, unpublished observations), support the concept 
that  the extent to which circulating AII antibody neutralizes a  given dose of 
angiotensin is largely dependent on the site at which AII is released into the cir- 
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The significance of these findings in vivo is as follows. Since AI is released by 
endogenous  renin  from renin  substrate  throughout  the  entire  circulation,  it 
would be expected that a  significant proportion of the AI would be liberated 
within the arterial tree,  to be converted to AII intramurally, close to receptor 
sites.  Our  Group  3  results  show  that AII antibody does not  neutralize  such 
locally converted AII as efficiently as it does lung-generated AII. It would thus 
be possible for endogenous AI, converted intramurally, in the region of arterio- 
lar receptors, to completely escape neutralization  by high titers of circulating 
AII antibody. Such an occurrence would, on the other hand, be less likely in the 
presence of lower molecular weight  blockers of the  renin-angiotensin  system, 
such  as inhibitors  of converting enzyme (5,  6),  or specific antagonists of AII 
which compete for AII at the receptor sites (18). 
The results may thus offer a partial explanation for the success of renin pre-inhibitor 
(19), angiotensin  converting enzyme inhibitor  (20), and specific competitive antago- 
nists of AII (21) in reducing blood pressure of 2-kidney  Goldblatt renal-clip hyperten- 
sive rats, where  studies  relying  on AII antibodies have failed  (10-12).  However, the 
failure of circulating AI antibodies to ameliorate renal-clip  hypertension (13) is less 
readily explained,  unless all steps in the reaction, including  the generation of AI by 
renin, can occur intramurally (22). 
Finally, though our results make it clear that extrapulmonary conversion to 
AII contributes to the total systemic pressor activity of AI released on the arterial 
side of the circulation, they do not support the conclusion of Freer and Stewart 
(9)  that, in contrast to most species, the pulmonary vasculature of the rat ap- 
pears not to be involved at all in the conversion of AI. In every experiment in 
Groups 3  and 4,  before AII antibody administration,  intra-arterial AI gave a 
smaller response than the equimolar dose of intravenous AI (P <  0.001). 
It would thus appear that the lungs are the most effective site for activation 
of AI, but that extrapulmonary local tissue conversion of AI to AII occurs to a 
sufficient extent to  render AII immunity an inefficient means of blocking the 
systemic pressor activity of the renin-angiotensin system. 
SUMMARY 
The effect of antibodies against angiotensin II (All) on systemic pressor re- 
sponses to intravenously injected All and angiotensin I  (AI) was studied in a 
group of bioassay rats. All antibody was only 29 % as effective in neutralizing AI 
given intravenously as it was in neutralizing All injected by the same  route. 
Control plasma caused no change in the relative potencies of AI and All. 
In a further series of experiments, All antibody was significantly less effec- 
tive in blocking intra-arterial AI than in blocking intravenous AI. The potency 
of intra-arterial AI, initially less than that of intravenous AI, became nearly 
twice that of intravenous AI after antibody administration, a result which could 
not occur if AI were inactive before lung transit. Thus, AI can elicit systemic HELEN  F.  OATES  AND  GORDON  S.  STOKES  85 
pressor activity independently of pulmonary conversion to AII. However, since 
the intra-arterial  AI responses were abolished by an inhibitor of angiotensin- 
converting enzyme,  the  activity would  appear  to be mediated  by peripheral 
conversion to AII rather than by an intrinsic action of the decapeptide. 
Both  series  of  experiments  suggest  that  the  efficacy  of  AII  antibody  in 
abolishing the systemic pressor activity of AI is highly dependent on the site of 
conversion of the AI to AII. The occurrence of localized intramural conversion 
of AI to AII near arteriolar receptors in vivo may so minimize exposure of the 
liberated  AII to  circulating  antibody  as  to  render  AII immunization  an  in- 
efficient means of blocking endogenous pressor activity of the renin-angiotensin 
system. 
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